Breast Cancer

T-DM1 Toxicity Management in Breast Cancer

April 05, 2021

Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.

FDA Defers Decision on Pembrolizumab for TNBC: Here's Why

March 30, 2021

Ahead of the Prescription Drug User Fee Act action date for the application, the regulatory agency’s Oncologic Drugs Advisory Committee voted 10 to 0 that a decision be deferred until further findings from KEYNOTE-522 trial become available.

Palbociclib/Letrozole Improves Survival in HR+ Metastatic Breast Cancer

March 26, 2021

Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting.